NO20000736L - FremgangsmÕte ved bestemmelse av transformerende effekt hos et transformerende middel - Google Patents

FremgangsmÕte ved bestemmelse av transformerende effekt hos et transformerende middel

Info

Publication number
NO20000736L
NO20000736L NO20000736A NO20000736A NO20000736L NO 20000736 L NO20000736 L NO 20000736L NO 20000736 A NO20000736 A NO 20000736A NO 20000736 A NO20000736 A NO 20000736A NO 20000736 L NO20000736 L NO 20000736L
Authority
NO
Norway
Prior art keywords
apoptin
cells
cancer
normal
agents
Prior art date
Application number
NO20000736A
Other languages
English (en)
Other versions
NO326659B1 (no
NO20000736D0 (no
Inventor
Mathieu Hubertus Mari Noteborn
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Publication of NO20000736D0 publication Critical patent/NO20000736D0/no
Publication of NO20000736L publication Critical patent/NO20000736L/no
Publication of NO326659B1 publication Critical patent/NO326659B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Measurement Of Current Or Voltage (AREA)
  • Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
NO20000736A 1997-08-12 2000-02-14 Fremgangsmate ved bestemmelse av transformerende effekt hos et mulig transformerende middel ved bestemmelse av apoptoseinduserende aktivitet NO326659B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97202501 1997-08-12
PCT/NL1998/000457 WO1999008108A1 (en) 1997-08-12 1998-08-11 Determining the transforming capability of agents

Publications (3)

Publication Number Publication Date
NO20000736D0 NO20000736D0 (no) 2000-02-14
NO20000736L true NO20000736L (no) 2000-04-11
NO326659B1 NO326659B1 (no) 2009-01-26

Family

ID=8228640

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000736A NO326659B1 (no) 1997-08-12 2000-02-14 Fremgangsmate ved bestemmelse av transformerende effekt hos et mulig transformerende middel ved bestemmelse av apoptoseinduserende aktivitet

Country Status (16)

Country Link
US (1) US6528247B1 (no)
EP (1) EP1004021B1 (no)
JP (1) JP4287588B2 (no)
KR (1) KR20010022812A (no)
AT (1) ATE283478T1 (no)
AU (1) AU756587B2 (no)
BR (1) BR9811163A (no)
CA (1) CA2301401C (no)
CZ (1) CZ299874B6 (no)
DE (1) DE69827805T2 (no)
NO (1) NO326659B1 (no)
NZ (1) NZ502800A (no)
PL (1) PL196605B1 (no)
RU (1) RU2214598C2 (no)
SK (1) SK286235B6 (no)
WO (1) WO1999008108A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW514581B (en) * 1999-09-02 2002-12-21 Ciba Sc Holding Ag A method of protecting wood against light-induced degradation by treatment with an impregnation which penetrates the surface of the wood
PT1083224E (pt) * 1999-09-02 2007-03-30 Leadd Bv Proteína associada a apoptina
JP2003516152A (ja) 1999-12-10 2003-05-13 レアト ベー．フェー． アポプチン会合タンパク質
EP1199363A1 (en) 2000-10-20 2002-04-24 Leadd B.V. Phosphorylation modifications of apoptin
DE60229924D1 (de) * 2001-03-30 2009-01-02 Leadd Bv Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
AU2003904086A0 (en) 2003-08-04 2003-08-21 Cochlear Limited Implant battery short circuit protection
RU2325200C2 (ru) * 2006-02-20 2008-05-27 Федеральное государственное унитарное предприятие "НПО Астрофизика" Способ лазерного подавления роста и элиминации злокачественных образований
RU2340349C2 (ru) * 2006-08-10 2008-12-10 Геннадий Петрович Македонов Способ стимулирования апоптоза
CA2822938A1 (en) 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
CA2850291A1 (en) 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
US10946104B2 (en) 2012-01-13 2021-03-16 Apo-Tb.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002008A (nl) 1990-09-12 1992-04-01 Stichting Centr Diergeneeskund Recombinant dna en rna en daarvan afgeleide produkten.
AU650936B2 (en) * 1991-01-15 1994-07-07 Oy Biotie Therapies Ltd Detection of syndecan content in biological materials such as tissues and body fluids for indications of malignant transformations of cells
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
SK278857B6 (sk) * 1992-03-19 1998-04-08 Prírodovedecká Fakulta Uk Spôsob testovania cytotoxicity a genotoxicity chem
NZ309171A (en) * 1995-06-07 2000-04-28 Leadd Bv use of apoptin as an antitumour agent which specifically kills tumour and not normal cells
JPH1015250A (ja) 1996-06-28 1998-01-20 Sega Enterp Ltd ゲーム装置
EP0927757A1 (en) * 1997-12-03 1999-07-07 Leadd B.V. Methods and means for inducing apoptosis by interfering with Bip-like proteins
EP0921192A1 (en) * 1997-12-03 1999-06-09 Leadd B.V. Molecules interacting with apoptin

Also Published As

Publication number Publication date
EP1004021B1 (en) 2004-11-24
DE69827805T2 (de) 2005-12-15
JP2001512829A (ja) 2001-08-28
AU756587B2 (en) 2003-01-16
WO1999008108A1 (en) 1999-02-18
EP1004021A1 (en) 2000-05-31
CA2301401A1 (en) 1999-02-18
NZ502800A (en) 2002-10-25
NO326659B1 (no) 2009-01-26
NO20000736D0 (no) 2000-02-14
RU2214598C2 (ru) 2003-10-20
CZ299874B6 (cs) 2008-12-17
PL338683A1 (en) 2000-11-20
PL196605B1 (pl) 2008-01-31
ATE283478T1 (de) 2004-12-15
US6528247B1 (en) 2003-03-04
DE69827805D1 (de) 2004-12-30
JP4287588B2 (ja) 2009-07-01
BR9811163A (pt) 2000-07-25
CZ2000479A3 (cs) 2000-06-14
KR20010022812A (ko) 2001-03-26
CA2301401C (en) 2008-10-21
AU8752998A (en) 1999-03-01
SK1902000A3 (en) 2000-11-07
SK286235B6 (sk) 2008-06-06

Similar Documents

Publication Publication Date Title
NO20000736D0 (no) Fremgangsmåte ved bestemmelse av transformerende effekt hos et transformerende middel
Akao et al. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro
Yu et al. Angiogenesis is inhibitory for mammalian digit regeneration
NZ502527A (en) Catalytic monoclonal antibodies raised to proteins in aggregated form, and use to treat alzheimers, atherosclerosis, amyloidosis and prions disease
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
ATE226643T1 (de) Genetische diagnose und pharmazeutische produkte zur behandlung von prostatakrebs
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
DK0759765T3 (da) Ekstrakter af hajbrusk med anti-angiogenisk aktivitet og en effekt på tumorregression samt en proces til fremstilling af disse
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
NO920125D0 (no) Fremgangsmaate for aa bestemme den funksjonelle aktivitetentil fri protein s eller protein c i en plasma-proeve
DE69735436D1 (de) Methode zum nachweis von zell-apoptose
Idkowiak-Baldys et al. Growth differentiation factor 11 (GDF11) has pronounced effects on skin biology
DE69940980D1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
WO2000018961A3 (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
NO994750L (no) Anti-Fas-antistoffer
WO1999028461A3 (en) Methods and means for inducing apoptosis by interfering with bip-like proteins
Vater Ultrastructural and immunocytochemical observations on the superior olivary complex of the mustached bat
Verzé et al. Distribution of GAP‐43 nerve fibers in the skin of the adult human hand
Sobczak et al. Effects of electromagnetic field on free-radical processes in steelworkers. Part II: Magnetic field influence on vitamin A, E and selenium concentrations in plasma
DK0848757T3 (da) Anvendelse af WAP eller MMTV regulatoriske sekvenser for målrettet ekspression af sammenkædede heterologe gener i humane mammae celler, inklusiv humane mammae carcinoma celler
ATE275200T1 (de) Genabgabe-vehikel die das apoptosis vp2 inducierendes protein, und/oder apoptin exprimiert
DE69636041D1 (de) Nachweis von brusttumorvirus-artigen sequenzen in brustkrebs bei menschen
ATE363072T1 (de) Monoklonaler antikörper gegen mxa und mxb
DE69532611D1 (de) Mittel zur behandlung von autoimmunkrankheiten
RU94024337A (ru) Антиметастатическое средство

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees